keyword
MENU ▼
Read by QxMD icon Read
search

cutaneous B cell lymphoma

keyword
https://www.readbyqxmd.com/read/28638263/cutaneous-presentation-of-diffuse-large-b-cell-lymphoma
#1
Robin George Manappallil, Abhay Mani Martin, Neena Mampilly, Kunivayalil Sajeevan
No abstract text is available yet for this article.
June 2017: Eurasian Journal of Medicine
https://www.readbyqxmd.com/read/28631652/primary-cutaneous-large-b-cell-lymphoma-of-scalp-case-report-of-a-rare-variant
#2
Yasmeen Khatib, Madhura Dande, Richa D Patel, Meena Makhija
Primary cutaneous large B-cell lymphoma (Bcl) is defined as a lymphoma composed of large cells constituting more than 80% of the infiltrate and absence of extracutaneous involvement after staging investigations. In the new World Health Organization/European Organization for Research and Treatment of Cancer classification, cutaneous Bcls with large cells are of three types - primary cutaneous large Bcl leg type (PCLBCLLT), primary cutaneous follicle center lymphoma diffuse type (PCFCLDT), and primary cutaneous large Bcls other (PCLBCLO)...
April 2017: Indian Journal of Pathology & Microbiology
https://www.readbyqxmd.com/read/28614957/associated-hematolymphoid-malignancies-in-patients-with-lymphomatoid-papulosis-a-canadian-retrospective-study
#3
Mohanad AbuHilal, Scott Walsh, Neil Shear
BACKGROUND: Lymphomatoid papulosis is one of the primary cutaneous CD30+ T-cell lymphoproliferative disorders. Although considered a benign disease, lymphomatoid papulosis has been associated potentially with an increased risk of secondary hematolymphoid malignancies. OBJECTIVE: The aim of this study was to assess the clinical characteristics and histologic subtypes of lymphomatoid papulosis, identify the prevalence and types of secondary hematolymphoid malignancies, and determine the potential risk factors for development of these hematolymphoid malignancies...
June 1, 2017: Journal of Cutaneous Medicine and Surgery
https://www.readbyqxmd.com/read/28595473/cd4-cd26-lymphocytes-are-useful-to-assess-blood-involvement-and-define-b-ratings-in-cutaneous-t-cell-lymphoma
#4
Eric C Vonderheid, J Steve Hou
Bernengo et al. reported that >30% CD4(+)CD26(-) lymphocytes detect blood involvement in patients with mycosis fungoides (MF) and Sézary syndrome. In addition, the ISCL/EORTC suggested that this threshold might serve as a criterion for the B2 blood rating for staging. In this manuscript, we report our experience with measurement of CD4(+)CD26(-) and CD4(+)CD7(-) cells, Sézary cell counts, and aberrant T cells with diminished expression of CD2, CD3, or CD5 antigens. CD4(+)CD26(-) ≥30% occurred in 15 of 373 (4...
June 9, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28594133/diagnostic-value-of-stmn1-lmo2-hgal-aid-expression-and-1p36-chromosomal-abnormalities-in-primary-cutaneous-b-cell-lymphomas
#5
Evelyne Verdanet, Olivier Dereure, Céline René, Ariane Tempier, Assia Benammar-Hafidi, Mathieu Gallo, Eric Frouin, Luc Durand, Isabelle Gazagne, Valérie Costes-Martineau, Valère Cacheux, Vanessa Szablewski
INTRODUCTION: distinction between primary cutaneous follicular lymphoma (PCFL) and primary cutaneous marginal zone lymphoma (PCMZL) is challenging as clear-cut immunophenotypic and cytogenetic criteria to segregate both entities are lacking. MATERIALS AND METHODS: to better characterize PCFL and PCMZL and to define criteria helpful for the differential diagnosis, we compared expression of immunohistochemical markers (LMO2, HGAL, STMN1, AID, MNDA) and the presence of cytogenetic abnormalities previously described in nodal follicular lymphoma (BCL2 and BCL6 breaks, 1p36 chromosomal region deletion (del 1p36)) in a series of 48 cutaneous follicular and marginal zone lymphomas (CFL and CMZL)...
June 8, 2017: Histopathology
https://www.readbyqxmd.com/read/28591206/erbb3-a-potential-serum-biomarker-for-early-detection-and-therapeutic-target-for-devil-facial-tumour-1-dft1
#6
Dane A Hayes, Dale A Kunde, Robyn L Taylor, Stephen B Pyecroft, Sukhwinder Singh Sohal, Elizabeth T Snow
Devil Facial Tumour 1 (DFT1) is one of two transmissible neoplasms of Tasmanian devils (Sarcophilus harrisii) predominantly affecting their facial regions. DFT1's cellular origin is that of Schwann cell lineage where lesions are evident macroscopically late in the disease. Conversely, the pre-clinical timeframe from cellular transmission to appearance of DFT1 remains uncertain demonstrating the importance of an effective pre-clinical biomarker. We show that ERBB3, a marker expressed normally by the developing neural crest and Schwann cells, is immunohistohemically expressed by DFT1, therefore the potential of ERBB3 as a biomarker was explored...
2017: PloS One
https://www.readbyqxmd.com/read/28567289/primary-cutaneous-b-cell-lymphoma-and-chronic-leg-ulcers-in-a-patient-with-type-2-diabetes
#7
Alessandro Mantovani, Fabrizia Perrone, Vincenzo Stoico, Isabella Pichiri, Laura Salvotelli, Ilaria Teobaldi, Massimiliano Bruti, Michela Conti, Luca Cima, Albino Eccher, Enzo Bonora
The incidences of type 2 diabetes mellitus and many cancers are rapidly increasing worldwide. Diabetes is a strong risk factor for some cancers (including lymphomas) and is also associated with adverse cancer outcomes. After gastrointestinal tract, the skin is the second most frequent extranodal site involved by non-Hodgkin lymphomas and the cutaneous B-cell lymphomas (CBCLs) range from 25% to 30% of all primary cutaneous lymphomas. The primary cutaneous diffuse large B-cell lymphoma (PCDLBCL) is an aggressive lymphoma with a poor prognosis, representing roughly 20% of all primary CBCLs...
2017: Endocrinology, Diabetes & Metabolism Case Reports
https://www.readbyqxmd.com/read/28553616/the-oncolytic-virotherapy-era-in-cancer-management-prospects-of-applying-h-1-parvovirus-to-treat-blood-and-solid-cancers
#8
Assia L Angelova, Mathias Witzens-Harig, Angel S Galabov, Jean Rommelaere
Non-Hodgkin lymphoma (NHL) and leukemia are among the most common cancers worldwide. While the treatment of NHL/leukemia of B-cell origin has much progressed with the introduction of targeted therapies, few treatment standards have been established for T-NHL/leukemia. As presentation in both B- and T-NHL/leukemia patients is often aggressive and as prognosis for relapsed disease is especially dismal, this cancer entity poses major challenges and requires innovative therapeutic approaches. In clinical trials, oncolytic viruses (OVs) have been used against refractory multiple myeloma (MM)...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/28547875/primary-cutaneous-b-cell-lymphoblastic-lymphoma-arising-from-a-long-standing-lesion-in-a-child-and-review-of-the-literature
#9
Hannah Song, Patricia Todd, Roberto Chiarle, Amy L Billett, Stephen Gellis
Precursor B-cell lymphoblastic lymphoma (B-LBL) is a rare entity and primary cutaneous B-LBL is an even more uncommon diagnosis that typically affects children. A 4-year-old boy presented with a persistent rash on his left cheek for almost 2 years and was found to have primary cutaneous B-LBL. We report this case to emphasize that B-LBL should be in the differential diagnosis for an otherwise unimpressive persistent lesion in the head and neck region and review all reported pediatric cases of primary cutaneous B-LBL without extracutaneous involvement...
May 26, 2017: Pediatric Dermatology
https://www.readbyqxmd.com/read/28543967/central-nervous-system-involvement-of-primary-cutaneous-diffuse-large-b-cell-lymphoma-leg-type-13-cases
#10
LETTER
E Gardette, A Maraval, F Brunet-Possenti, G Quereux, H Beltraminelli, I Templier, J Hodel, E Scherman, E Durot, M Bagot, A Pham-Ledard, F Grange, M Beylot-Barry, S Ingen-Housz-Oro
No abstract text is available yet for this article.
May 23, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28532760/research-techniques-made-simple-high-throughput-sequencing-of-the-t-cell-receptor
#11
Tiago R Matos, Menno A de Rie, Marcel B M Teunissen
High-throughput sequencing (HTS) of the T-cell receptor (TCR) is a rapidly advancing technique that allows sensitive and accurate identification and quantification of every distinct T-cell clone present within any biological sample. The relative frequency of each individual clone within the full T-cell repertoire can also be studied. HTS is essential to expand our knowledge on the diversity of the TCR repertoire in homeostasis or under pathologic conditions, as well as to understand the kinetics of antigen-specific T-cell responses that lead to protective immunity (i...
June 2017: Journal of Investigative Dermatology
https://www.readbyqxmd.com/read/28529555/detection-of-p53-and-bcl-2-expression-in-cutaneous-hemangioma-through-the-quantum-dot-technique
#12
Tian Tang, Duan-Lian Zhang
Hemangioma is one of the most common types of infantile vascular benign tumor. The aim of the present study was to investigate the role of B-cell lymphoma 2 (Bcl-2) and tumor protein p53 (p53) in the proliferation and apoptosis of hemangioma cells. A total of 38 paraffin-embedded hemangioma specimens (16 males and 22 females) and another 5 paraffin-embedded healthy surrounding tissue samples, collected between January 2007 and December 2010, were obtained from the Department of Pathology at Renmin Hospital of Wuhan University (Wuhan, China)...
May 2017: Oncology Letters
https://www.readbyqxmd.com/read/28526298/regulation-of-the-glycerol-transporter-aquaporin-3-by-histone-deacetylase-3-and-p53-in-keratinocytes
#13
Vivek Choudhary, Lawrence O Olala, Karen Kagha, Zhi-Qiang Pan, Xunsheng Chen, Rong Yang, Abigail Cline, Inas Helwa, Lauren Marshall, Ismail Kaddour-Djebbar, Meghan E McGee-Lawrence, Wendy B Bollag
Aquaporin-3 (AQP3), a water and glycerol channel, plays an important role in epidermal function, with studies demonstrating its involvement in keratinocyte proliferation, differentiation and migration and epidermal wound healing and barrier repair. Increasing speculation about the use of histone deacetylase (HDAC) inhibitors to treat skin diseases led us to investigate HDAC's role in the regulation of AQP3. The broad-spectrum HDAC inhibitor, suberolyanilide hydroxamic acid (SAHA) induced AQP3 mRNA and protein expression in a dose- and time-dependent manner in normal keratinocytes...
May 16, 2017: Journal of Investigative Dermatology
https://www.readbyqxmd.com/read/28504999/tumor-microenvironment-and-checkpoint-molecules-in-primary-cutaneous-diffuse-large-b-cell-lymphoma-new-therapeutic-targets
#14
Christina Mitteldorf, Arbeneshe Berisha, Monique C Pfaltz, Sigrid M C Broekaert, Michael P Schön, Katrin Kerl, Werner Kempf
Programmed death ligand 1 (PD-L1) is expressed by 20% to 57% of systemic diffuse large B cell lymphomas (DLBCLs). PD-L1 expression in primary cutaneous DLBCL (pcDLBCL) has not been studied so far. Sixteen paraffin-embedded tissue samples of pcDLBCL (13 leg type [LT], 3 others [OT]) were investigated for PD-1, PD-L1, and CD33 expression and the cellular composition of the tumor microenvironment, focusing on myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages. Membrane-bound PD-L1 expression by the tumor cells was observed in all samples, albeit to a variable extent (19...
May 12, 2017: American Journal of Surgical Pathology
https://www.readbyqxmd.com/read/28479318/identification-of-somatic-mutations-in-primary-cutaneous-diffuse-large-b-cell-lymphoma-leg-type-by-massive-parallel-sequencing
#15
Sylvain Mareschal, Anne Pham-Ledard, Pierre Julien Viailly, Sydney Dubois, Philippe Bertrand, Catherine Maingonnat, Maxime Fontanilles, Elodie Bohers, Philippe Ruminy, Isabelle Tournier, Philippe Courville, Bernard Lenormand, Anne Bénédicte Duval, Emilie Andrieu, Laurence Verneuil, Beatrice Vergier, Hervé Tilly, Pascal Joly, Thierry Frebourg, Marie Beylot-Barry, Jean-Philippe Merlio, Fabrice Jardin
To determine whether the mutational profile of primary cutaneous diffuse large B-cell lymphoma leg-type (PCLBCL-LT) is unique by comparison with other diffuse large B-cell lymphoma (DLBCL) subtypes, we analyzed a total cohort of 28 PCLBCL-LT cases by next generation sequencing with a Lymphopanel designed for DLBCL. We also analyzed 12 pairs of tumor and control DNA samples by whole exome sequencing which led us to perform resequencing of three selected genes not included in the Lymphopanel: TBL1XR1, KLHL6 and IKZF3...
May 4, 2017: Journal of Investigative Dermatology
https://www.readbyqxmd.com/read/28468169/b-cell-lymphoma-underlying-paraffinoma-of-glabella
#16
Jin An Cha, Bomi Kim, Kyung Ah Lee
Soft tissue reactions to paraffin include inflammation, fibrosis, disfigurement, and granulomatous inflammation with foreign body giant cell reaction. The authors report the case of a 77-year-old woman with cutaneous marginal zone B cell lymphoma located on glabella, arising in association with underlying paraffinoma. While it is unclear whether the implant directly contributed to the development of lymphoma, this association has not been previously documented, prompting this report.
May 2017: Journal of Craniofacial Surgery
https://www.readbyqxmd.com/read/28461685/intravascular-large-b-cell-lymphoma-presenting-as-fever-of-unknown-origin-and-diagnosed-by-random-skin-biopsies-a-case-report-and-literature-review
#17
Horacio di Fonzo, Damian Contardo, Diego Carrozza, Paola Finocchietto, Adriana Rojano Crisson, Cecilia Cabral, Maria de Los Angeles Juarez
BACKGROUND Intravascular lymphoma (IVL) is a rare lymphoproliferative disorder characterized by the proliferation of large B lymphoma cells within the lumen of small-caliber blood vessels. Clinical features are nonspecific, presenting as a systemic disease with fever and may be life-threatening. Antemortem diagnosis is difficult but may be made with biopsies of affected tissues or with random skin biopsies. CASE REPORT We report the case of a 66-year-old white woman presenting with fever of unknown origin (FUO) who developed neurologic, pulmonary, and hematologic manifestations...
May 2, 2017: American Journal of Case Reports
https://www.readbyqxmd.com/read/28459613/impact-of-expert-pathologic-review-of-lymphoma-diagnosis-study-of-patients-from-the-french-lymphopath-network
#18
Camille Laurent, Marine Baron, Nadia Amara, Corinne Haioun, Mylène Dandoit, Marc Maynadié, Marie Parrens, Beatrice Vergier, Christiane Copie-Bergman, Bettina Fabiani, Alexandra Traverse-Glehen, Nicole Brousse, Marie-Christine Copin, Patrick Tas, Tony Petrella, Marie-Christine Rousselet, Josette Brière, Fréderic Charlotte, Catherine Chassagne-Clement, Thérèse Rousset, Luc Xerri, Anne Moreau, Antoine Martin, Diane Damotte, Peggy Dartigues, Isabelle Soubeyran, Michel Peoch, Pierre Dechelotte, Jean-François Michiels, Antoine de Mascarel, Françoise Berger, Céline Bossard, Flavie Arbion, Isabelle Quintin-Roué, Jean-Michel Picquenot, Martine Patey, Blandine Fabre, Henri Sevestre, Cécile Le Naoures, Marie-Pierre Chenard-Neu, Claire Bastien, Sylvie Thiebault, Laurent Martin, Manuela Delage, Thomas Filleron, Gilles Salles, Thierry Jo Molina, Georges Delsol, Pierre Brousset, Philippe Gaulard
Purpose To prospectively assess the clinical impact of expert review of lymphoma diagnosis in France. Materials and Methods From January 2010 to December 2013, 42,145 samples from patients with newly diagnosed or suspected lymphomas were reviewed, according to the 2008 WHO classification, in real time by experts through the Lymphopath Network. Changes in diagnosis between referral and expert review were classified as major or minor according to their potential impact on patient care. Results The 42,145 reviewed samples comprised 36,920 newly diagnosed mature lymphomas, 321 precursor lymphoid neoplasms, 314 myeloid disorders, and 200 nonhematopoietic neoplasms, with 4,390 benign lesions...
June 20, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28426350/lenalidomide-maintenance-compared-with-placebo-in-responding-elderly-patients-with-diffuse-large-b-cell-lymphoma-treated-with-first-line-rituximab-plus-cyclophosphamide-doxorubicin-vincristine-and-prednisone
#19
Catherine Thieblemont, Hervé Tilly, Maria Gomes da Silva, Rene-Olivier Casasnovas, Christophe Fruchart, Franck Morschhauser, Corinne Haioun, Julien Lazarovici, Anida Grosicka, Aurore Perrot, Judith Trotman, Catherine Sebban, Dolores Caballero, Richard Greil, Koen van Eygen, Amos M Cohen, Hugo Gonzalez, Reda Bouabdallah, Lucie Oberic, Bernadette Corront, Bachra Choufi, Armando Lopez-Guillermo, John Catalano, Achiel Van Hoof, Josette Briere, Jose Cabeçadas, Gilles Salles, Philippe Gaulard, Andre Bosly, Bertrand Coiffier
Purpose The standard treatment of patients with diffuse large B-cell lymphoma (DLBCL) is rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Lenalidomide, an immunomodulatory agent, has shown activity in DLBCL. This randomized phase III trial compared lenalidomide as maintenance therapy with placebo in elderly patients with DLBCL who achieved a complete response (CR) or partial response (PR) to R-CHOP induction. Methods Patients with previously untreated DLBCL or other aggressive B-cell lymphoma were 60 to 80 years old, had CR or PR after six or eight cycles of R-CHOP, and were randomly assigned to lenalidomide maintenance 25 mg/d or placebo for 21 days of every 28-day cycle for 24 months...
April 20, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28408397/the-il-31-il-31-receptor-axis-general-features-and-role-in-tumor-microenvironment
#20
REVIEW
Elisa Ferretti, Anna Corcione, Vito Pistoia
IL-31 is a recently identified cytokine with a well-defined role in the pathogenesis of pruritus. IL-31, whose production is induced by IL-4 and IL-33, binds a heterodimeric receptor (R) composed of the exclusive IL-31RA chain and the shared oncostatin M R. Signaling through the IL-31R involves the MAPK, PI3K/AKT and Jak/STAT pathways. Different variants and isoforms of IL-31RA with different signaling activities have been identified. IL-31 is produced predominantly by circulating Th2 lymphocytes and skin-homing CLA(+)CD45RO(+) T cells...
April 13, 2017: Journal of Leukocyte Biology
keyword
keyword
85921
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"